From: Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever
Parameters
At least 50% reduction
Attack frequency
63/65 (96.9%)
Durations of attacks
Patients VAS
64/65 (98.5%)
Physicians VAS
CRP (at least 2 weeks after the last attack)
62/65 (95.3%)
Arthritis
9/11 (81.8%)